Clinical Trial Search

Primary: Overall Response (OR) Rate — 0.07 Proportion of participants

Primary: Complete Remission — 10 participants

Primary: Maximum Tolerated Dose — 200 milligrams PO daily

Primary: Event-free Survival (EFS) Per Blinded Independent Review Committee (BIRC) Assessment — 3.0; 3.0 months — p== 0.694

Primary: Objective Response Rate — 2; 4; 6; 17 Participants

Primary: Incidence of Dose Limiting Toxicities (DLTs) — 0; 0; 1 Participants

Primary: Number of Participants With Objective Response — 1; 2; 14; 6 Participants

Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients

Primary: Maximum Tolerated Dose of CpG 7909 as Determined Using the Number of Participants With a DLT at Each Dose Level — 0; 1; 0; 1 participants

Primary: Objective Tumor Response — 0 participants

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Overall Response Rate — 0.0 proportion of participants

Primary: Percentage of Participants With 3-year Progression-free Survival (PFS) — 90 percentage of participants

Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants

Primary: Progression-free Survival (PFS) at 2 Years — 69 percentage of participants

Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Progression-free Survival at 1 Year — 38 percentage of participants

Primary: Overall Response Rate (Complete and Partial Responses) as Defined by the International Workshop Criteria — 62.5; 52.4 percentage of patients

Primary: Complete Response Rate of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) and Pralatrexate (P) Treatment — 52 percentage of participants analyzed

Primary: Objective Overall Response Rate — 14; 0 participants — p=0.022

Primary: Progression-free Survival — 89 percentage of participants

Primary: Number of Patients With Response — 0; 2 participants

Primary: 2-year Overall Survival Rates — 71.1; 73.7 percentage of participants

Primary: Clinical Response Rate — 1; 7; 0; 8 Participants

Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg

Primary: 2-year Overall Survival Rate — 31 percentage of participants

Primary: Overall Response Rate (ORR) as Determined by Local Investigator — 32.1 Percentage of participants

Primary: Number of Participants With Response (Complete Response or Progressive Disease) — 2; 6 Participants

Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0 Participants

Primary: Response Rate of Patients After 2 Courses of Chemotherapy — 45.2; 44.0 percentage of response — p=0.005